Navigation Links
Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies, Finds Frost & Sullivan
Date:2/20/2013

k faster and long-lasting wound healing solutions. Reacting to customer demand, manufacturers are adopting best practices to design wound dressings that provide tight control over the dressing's adsorption and fluid handling properties.

There is a surge in the number of wound healing technology platforms awaiting commercialization and multiple start-up firms and spin-offs from academia are working on procuring funds and partnerships for commercialization. Both Tier 1 and emerging companies are engaged in intense R&D to develop dressings that accelerate healing.

"Emerging companies that focus on every type of wound at each phase of the wound healing process will be able to provide innovative solutions," noted Frost & Sullivan Technical Insights Industry Analyst Prasanna Vadhana Kannan. "One of the noteworthy wound care solutions are advanced wound dressings that can assist in the complex task of tissue repair and efficiently remove bacterial biofilm formation."

Currently, there are no national or international standards to guide wound care dressing manufacturers, and the type of protocol adopted depends upon the physician's recommendation and patient's demand. This situation hinders the implementation and testing of affordable wound care platforms.

Standardization is vital since wound treatment relies heavily on proper wound bed preparation, the choice of wound dressings, and the patient's condition. Wound closure also depends on the use of appropriate products.

Researchers are striving to examine the importance of cell differentiation and tissue morphogenesis-based factors in faster wound healing. Manufacturers need greater clinical evidence to understand biological-mediated therapies and their role in improving the outcome of wound care.

"On the back of considerable research, wound care solutions are expected to have the capabilities to safeguard cells from apoptosis, and simultaneously stimulate rapid cell division
'/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lentigen Receives U.S. Orphan Drug Designation for Novel Gene Therapy for glioblastoma multiforme
2. Novelos Therapeutics Prices $5.5 Million Public Offering
3. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
4. RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
5. Frost & Sullivan Determines a Real and Urgent Need for Novel Cancer Diagnostics Tests
6. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
7. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
8. Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015
9. Oncologists in the United States and Europe Indicate that Novel Chemotherapies Hold the Most Near-Term Promise for Improving Outcomes in Soft Tissue Sarcoma
10. Insero Health Completes Phase I Trial of Novel Therapy in Patients With Drug Resistant Epilepsy
11. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... 11, 2014 Patient engagement has become ... organizations are turning to an assortment of marketing ... part of this evolving approach to patient engagement, ... and engage patients throughout their experiences with a ... By mapping the patient journey and employing a ...
(Date:7/11/2014)... 11, 2014 The consumer marketing playbook ... industry sectors to better identify winning tools and ... engage with and understand consumers, as new technologies ... critical purchasing decisions. According to ... one area where organizations can observe a deep ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... Dec. 17 Novavax, Inc.,(Nasdaq: NVAX ) ... recombinant trivalent seasonal influenza virus-like particle (VLP),vaccine. The ... two,influenza vaccine programs that Novavax is developing using ... candidate is,currently in Phase I/IIa clinical trials., ...
... Product Developed Through Joint Venture Between Bristol-Myers Squibb and ... First of Its Kind in HIV Treatment -, ... The European Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz ... ATRIPLA for commercialization in the,27 countries of the European ...
Cached Medicine Technology:Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 2Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9
(Date:7/12/2014)... (PRWEB) July 12, 2014 With prom ... dress manufacturer and retailer, is ready to showcase its ... its new collection of evening dresses in its online ... to 67% off) for these elegant gowns. According to ... an end on July 26, 2014. , He ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Wright & Schulte ... DePuy Orthopedics , Inc., a subsidiary of Johnson & Johnson, ... suffers chronic pain after receiving a metal-on-metal DePuy Pinnacle hip ... to remove the artificial hip implant. The DePuy hip lawsuit ... Northern District of Texas (Case No. 3:14-cv-2427) where DePuy ...
(Date:7/12/2014)... 2014 Doylestown Hospital recently conducted an ... men’s health questions. Paddock tackles topics including main ... women live longer than men, and testosterone replacement therapy, ... Simple featured on Doylestown Hospital’s website, Dr. Brad ... any age. If you notice pain, bulging, or asymmetry ...
(Date:7/12/2014)... Utah (PRWEB) July 12, 2014 Utah ... types of startups, with awards being bestowed to companies ... spotlighted Utah’s outstanding entrepreneur community with recognition for new ... sustainable model with incoming revenue. , 25 Under 5 ... the state that are under 5 years old. Award ...
(Date:7/12/2014)... A recent article released by Seattle's well ... suggestions for those seeking cosmetic surgical procedures in summer ... and the heat begins to enliven the rainy Pacific Northwest, ... realizing that they didn’t work out as much during the ... a sudden surge of people eager to look their best ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:SquareHook is Recognized for UVEF 25 Businesses Under 5 Years-Watch Out 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2
... , , YSA and ... , , WASHINGTON, Aug. 10 ... the second year to offer UnitedHealth HEROES grants to youth-led ... Educators, service-learning coordinators, and students in the health professions are ...
... Long-standing liver disease has long been recognized to result ... various international studies, the overall incidence has varied from ... However, the reason for this is poorly understood. With ... and offering complete cure and long-term survival, bone disease ...
... age than is normal, researchers note , MONDAY, Aug. 10 ... the attacks on the Twin Towers on 9/11 may be ... blood. , Notably, half of the cases identified among law ... is usually a disease of the elderly. , "This ...
... , , , , ... now participate in the advanced stuttering treatment program at Hollins Communications ... at a substantially reduced cost through 2009 thanks to new stuttering ... , HCRI,s scholarship program is designed to broaden accessibility ...
... RONKONKOMA, N.Y., Aug. 10 NBTY, Inc. (NYSE: ... marketer of nutritional supplements, today announced that it will web cast the ... the Canaccord Adams Global Growth Conference in Boston on Thursday, ... to be web cast live on the Company Web site, ...
... , ROCHESTER, N.Y., Aug. 10 Your sleeping problems ... as Fibromyalgia (FM), and Chronic Fatigue Syndrome (CFS). But it can ... , , Recent studies show that ... review written by Professor Mark Opp from the University of Michigan ...
Cached Medicine News:Health News:Youth Find Innovative Solutions to Leading Health Threat 2Health News:Youth Find Innovative Solutions to Leading Health Threat 3Health News:Youth Find Innovative Solutions to Leading Health Threat 4Health News:9/11 Responders May Be At Raised Myeloma Risk 2Health News:9/11 Responders May Be At Raised Myeloma Risk 3Health News:Hollins Communications Research Institute Announces More Stuttering Therapy Scholarships 2Health News:NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009 2Health News:NBTY to Web Cast Presentation at Canaccord Adams Global Growth Conference; Announces Preliminary Unaudited Net Sales Results for July 2009 3Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 2Health News:Surprise! Better Sleep with Gene-Eden(R), an Antiviral Supplement 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: